Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Gastrointestinal Stromal Tumors,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 07/11/2001, Revision: 35, Status: Authorised [PDF]
Case Medical Research, 2019 openalex +2 more sources
Positron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia. [PDF]
Turk Arch PediatrKaya Z +7 more
europepmc +2 more sources
Blood, 2015 Abstract Background: The Early T-cell precursor (ETP) variant of acute lymphoblastic lymphoma/leukemia (ALL) is a recognized high risk variant, recognized by the absence of CD1a, with aberrant myeloid antigen expression (CD13, CD33, CD117, and CD34), and frequent absence of CD4 or CD8. Treatment intensification may improve
Deniz Peker +6 more
openaire +3 more sources
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2017 Divya Shelly, Sumeet Gujral
openalex +5 more sources
Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma [PDF]
Blood, 2019 Sameer S. Khatri, Annette S. Kim
openalex +2 more sources
CBFA2T3::GLIS2‐positive acute leukemia with RAM and mixed T/megakaryocytic phenotype
eJHaem, 2023 Herein, we present a rare case of acute myeloid leukemia (AML) with CBFA2T3‐rearrangement and the expression of megakaryocytic and lymphoid markers, highlighting the need for a high suspicion index in differential diagnosis and applying adequate workup ...
Mahsa Khanlari +8 more
doaj +1 more source
American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023 Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb +12 more
wiley +1 more source
American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023 Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski +4 more
wiley +1 more source
The thioredoxin system: Balancing redox responses in immune cells and tumors
European Journal of Immunology, Volume 53, Issue 1, January 2023., 2023 The thioredoxin (TRX) system is a critical contributor to cellular redox homeostasis in all living cells. Here, we review the key roles of TRX for activation, proliferation, and responses in T cells, B cells, and myeloid cells. Further, we conceptualize how this knowledge may be therapeutically exploited for cancer treatment.
Jonathan Muri, Manfred Kopf
wiley +1 more source
Transformation of acute lymphoblastic leukemia with a precursor B-cell immunophenotype to burkitt’s lymphoma: A case report [PDF]
Caspian Journal of Internal Medicine, 2023 Background: As a new point, some very rare features can be revealed as initial diagnosis of acute lymphoblastic leukemia (ALL) without any evidence of lymphoma-like behavior which after initial recovery, presents with new evidence of lymphoma.
Masoumeh Jafari +2 more
doaj